1. Search Result
Search Result
Results for "

M2

" in MedChemExpress (MCE) Product Catalog:

378

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

3

Biochemical Assay Reagents

9

Peptides

2

Inhibitory Antibodies

47

Natural
Products

9

Recombinant Proteins

32

Isotope-Labeled Compounds

7

Antibodies

3

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101671

    M-2

    MMP Drug Metabolite Inflammation/Immunology
    S-methyl-KE-298 is an active metabolite of KE-298. KE-298 inhibits matrix metalloproteinase (MMP-1) production from rheumatoid arthritis (RA) synovial cells.
    S-methyl-KE-298
  • HY-P1783A

    Influenza Virus Infection
    M2e, human TFA, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A. M2e, human TFA is a valid and versatile vaccine candidate to protect against any strain of human influenza A .
    <em>M2</em>e, human TFA
  • HY-100341

    Others Others
    M2I-1 is a Mad2 inhibitor targeting the binding of Mad2 to Cdc20, an essential protein-protein interaction (PPI) within the spindle assembly checkpoint (SAC) .
    <em>M2</em>I-1
  • HY-75867

    Influenza Virus Infection
    M2 ion channel blocker is capable of inhibiting and blocking the activity of M2 ion channel;Antiviral agent.
    <em>M2</em> ion channel blocker
  • HY-P1783

    Influenza Virus Infection
    M2e, human, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A, which is a valid and versatile vaccine candidate to protect against any strain of human influenza A .
    <em>M2</em>e, human
  • HY-128769

    CDK Cancer
    M2N12 is a potent and highly selective cell division cycle 25C protein phosphatase (Cdc25C) inhibitor with an IC50 value of 0.09  μM. M2N12 also has promising activity against Cdc25A and Cdc25B with IC50 values of  0.53  μM and 1.39 μM, respectively. M2N12 has anti-tumor activity and can be used for cancer research .
    <em>M2</em>N12
  • HY-N3963

    (+)-Gomisin M2

    HIV Infection Neurological Disease Inflammation/Immunology Cancer
    Gomisin M2 ((+)-Gomisin M2) is a lignan isolated from the fruits of Schisandra rubriflora with anti-HIV activity (EC50 of 2.4 μM). Gomisin M2 exhibits anti-cancer and anti-allergic activities and has the potential for Alzheimer’s disease research [2].
    Gomisin <em>M2</em>
  • HY-N6700

    Parasite Cancer
    Aflatoxin M2 is a major metabolite of Aflatoxin B1. Aflatoxin M2 is a mycotoxin produced by the fungi Aspergillus flavus and Aspergillus parasiticus. The level of toxicity associated with Aflatoxin is Aflatoxin B1>Aflatoxin M1>Aflatoxin G1>Aflatoxin B2>Aflatoxin M2>Aflatoxin G2 .
    Aflatoxin <em>M2</em>
  • HY-128669
    Abemaciclib metabolite M2
    1 Publications Verification

    LSN2839567

    CDK Drug Metabolite Cancer
    Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s of 1.2 and 1.3 nM, respectively. Anti-cancer activity [2].
    Abemaciclib metabolite <em>M2</em>
  • HY-I0678S

    PDGFR Drug Metabolite Cancer
    Regorafénib N-oxyde-d3(M2) is the deuterium labeled Regorafénib N-oxyde M2[1]. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[2].
    Regorafénib N-oxyde-d3 (<em>M2</em>)
  • HY-I0678

    Drug Metabolite PDGFR Cancer
    Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
    Regorafénib N-oxyde (<em>M2</em>)
  • HY-N6700S

    Isotope-Labeled Compounds Cancer
    Aflatoxin M2- 13C17 is the 13C labeled Aflatoxin M2 (HY-N6700) . Aflatoxin M2 is a major metabolite of Aflatoxin B1. Aflatoxin M2 is a mycotoxin produced by the fungi Aspergillus flavus and Aspergillus parasiticus. The level of toxicity associated with Aflatoxin is Aflatoxin B1>Aflatoxin M1>Aflatoxin G1>Aflatoxin B2>Aflatoxin M2>Aflatoxin G2 [2].
    Aflatoxin <em>M2</em>-13C17
  • HY-162031

    JAK Metabolic Disease
    MMT3-72-M2 is an MMT3-72 metabolite. MMT3-72-M2 is a selective JAK1 inhibitor. MMT3-72-M2 inhibits JAK1, JAK2, TYK2, and JAK3 with IC50 values of 10.8 nM, 26.3 nM, 91.6 nM, 328.7 nM, respectlly .
    MMT3-72-<em>M2</em>
  • HY-149704

    mAChR Neurological Disease
    M1/M2/M4 muscarinic agonist 1 (Compound 42) is a muscarinic M4/M1/M2 agonist with EC50 values of 6.5, 26 and 210 nM for M4/M1/M2, respectively. M1/M2/M4 muscarinic agonist 1 can be used for research on mental diseases, such as schizophrenia, delusion, etc .
    M1/<em>M2</em>/M4 muscarinic agonist 1
  • HY-128669S

    LSN2839567-d6

    CDK Cancer
    Abemaciclib metabolite M2-d6 is the deuterium labeled Abemaciclib metabolite M2. Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s in the range of 1-3 nM. Anti-cancer activity[1][2].
    Abemaciclib metabolite <em>M2</em>-d6
  • HY-149731

    mAChR Neurological Disease
    M1/M2/M4 muscarinic agonist 2 (compound 43) is a muscarinic mAChR M1/M2/M4 agonist with EC50s of 30 nM, 200 nM and 6.2 nM, respectively .
    M1/<em>M2</em>/M4 muscarinic agonist <em>2</em>
  • HY-I0678S1

    Drug Metabolite Cancer
    Regorafénib N-oxyde (M2)- 13C,d3 is the 13C- and deuterium labeled Regorafénib N-oxyde (M2). Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
    Regorafénib N-oxyde (<em>M2</em>)-13C,d3
  • HY-149733

    mAChR Neurological Disease
    M1/M2/M4 muscarinic agonist 3 (compound 45) is a muscarinic mAChR M1/M2/M4 agonist with EC50s of 3.2 nM, 32 nM and 1.7 nM, respectively .
    M1/<em>M2</em>/M4 muscarinic agonist 3
  • HY-116294A

    mAChR Cardiovascular Disease
    Methoctramine tetrahydrochloride is a potent and cardioselectivity antagonist of M2 muscarinic receptor. Methoctramine tetrahydrochloride can inhibit Muscarine-induced bradycardia in vivo [2] .
    Methoctramine tetrahydrochloride
  • HY-147881

    Influenza Virus Infection
    Anti-Influenza agent 3 (compound 11h) is a potent anti-influenza agent with EC50 values of 3.29, 2.45 µM for A/HK/68 (H3N2, M2-WT), A/WSN/33 (H1N1, M2-S31N) strain, respectively. Anti-Influenza agent 3 shows low cytotoxicity for MDCK epithelial cells. Anti-Influenza agent 3 inhibits the M2 WT and S31N ion channel conductivity .
    Anti-Influenza agent 3
  • HY-112358

    CDK Neurological Disease Cancer
    GW8510 is a potent cyclin-dependent kinase-2 (CDK2) inhibitor. GW8510 is also a ribonucleotide reductase M2 (RRM2) inhibitor. GW8510 exhibits neuroprotective and anticancer activities [2] .
    GW8510
  • HY-155762

    NOD-like Receptor (NLR) Interleukin Related Neurological Disease Inflammation/Immunology
    Anti-neuroinflammation agent 1 is a potent anti-neuroinflammation agent that regulates polarization BV2 microglia cells from M1 phenotype to M2 phenotype .
    Anti-neuroinflammation agent 1
  • HY-107755

    4,4-Pentamethylenepiperidine hydrochloride

    Influenza Virus Infection
    3-Azaspiro[5.5]undecane (4,4-Pentamethylenepiperidine) hydrochloride is an inhibitor targeting the WT influenza A virus M2 (A/M2), with an IC50 of 1 μM .
    3-Azaspiro[5.5]undecane hydrochloride
  • HY-110124

    Pyruvate Kinase Cancer
    ML202 is a highly specific allosteric activator of human pyruvate kinase M2 (hPK-M2), which can affect the cooperativity of phosphoenolpyruvate (PEP) binding, while adenosine diphosphate (ADP) binding almost no effect .
    ML202
  • HY-15885

    mAChR Neurological Disease
    LY2119620 is a high-affinity muscarinic M2/M4 receptor agonist.
    LY2119620
  • HY-155792

    Others Others
    Troglitazone glucuronide (Compound M2) is an initial metabolite of troglitazone in the liver .
    Troglitazone glucuronide
  • HY-105793

    mAChR Neurological Disease
    Mazaticol is an anticholinergic agent. Mazaticol blocks the muscarinic acetylcholine receptors and cholinergic nerve activity. Mazaticol is a potent 3H-QNB and 3H-PZ binding inhibitor, can bind to the M2 receptors with high affinity. Mazaticol exhibits inhibitory effects on dopamine uptake in the striatal nerve terminal. Mazaticol can be used for parkinsonian syndrome research [2].
    Mazaticol
  • HY-101586

    Lu 25-109

    mAChR Neurological Disease
    Alvameline (Lu25-109) is a partial M1 agonist and M2/M3 antagonist.
    Alvameline
  • HY-157956

    mAChR Neurological Disease
    LASSBio-873 is an orally active muscarinic cholinergic receptor (mAChR) agonist that crosses the blood-brain barrier. LASSBio-873 has potent analgesic effects on acute and inflammatory pain. The analgesic effect of LASSBio-873 can be inhibited by intrathecal injection of the M2 receptor antagonist methoctramine .
    LASSBio-873
  • HY-B0402S

    1-Adamantanamine-d15; 1-Aminoadamantane-d15

    Influenza Virus Orthopoxvirus SARS-CoV Apoptosis Infection Neurological Disease Cancer
    Amantadine-d15 is the deuterium labeled Amantadine. Amantadine (1-Adamantanamine) is an antiviral agent with activity against influenza A viruses. Amantadine blocks the proton flow through the M2 ion channel (M2 proton channel of influenza A) and thus prevents the release of viral RNA into the cytoplasm of the infected cells. Amantadine is an antiparkinsonian agent[1][2].
    Amantadine-d15
  • HY-10082
    Triapine
    3 Publications Verification

    3-AP; PAN-811; OCX191

    DNA/RNA Synthesis Cancer
    Triapine (3-AP; PAN-811) is a potent inhibitor of the M2 subunit of ribonucleotide reductase (RR), and is a potent radiosensitizer.
    Triapine
  • HY-P1376A

    mAChR Adrenergic Receptor Endocrinology
    G-Protein antagonist peptide TFA is a truncated substance P-related peptide, competes with receptor for G protein binding. G-Protein antagonist peptide TFA inhibits the activation of Gi or Go by M2 muscarinic cholinergic receptor (M2 mAChR) or of Gs by beta-adrenergic receptor in the reconstituted phospholipid vesicles, assayed by receptor-promoted GTP hydrolysis .
    G-Protein antagonist peptide TFA
  • HY-B2116

    Oxaphenamide; 4'-Hydroxysalicylanilide

    HBV Infection
    Osalmid is a ribonucleotide reductase small subunit M2 (RRM2) targeting compound; suppresses ribonucleotide reductase activity with an IC50 of 8.23 μM.
    Osalmid
  • HY-101239

    Oxotremorine sesquifumarate is a mAChR agonist that mainly activates M2 receptors. Oxotremorine sesquifumarate can be used for neurological research [2].
    Oxotremorine sesquifumarate
  • HY-A0030

    mAChR Neurological Disease Metabolic Disease
    Fesoterodine Fumarate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine Fumarate is used for the overactive bladder (OAB) [2].
    Fesoterodine fumarate
  • HY-70053

    mAChR Neurological Disease Metabolic Disease
    Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB) [2].
    Fesoterodine
  • HY-N3248

    Momordicacoside G

    Endogenous Metabolite Reactive Oxygen Species Apoptosis Inflammation/Immunology Cancer
    Momordicoside G (Momordicacoside G) is an orally active cucurbitane-type triterpene glycoside. Momordicoside G selectively induces apoptosis of M1-like macrophages, without affecting M2-like macrophages. Momordicoside G reduces intracellular ROS levels and promotes autophagy. Momordicoside G also has anticancer activity, inhibiting the growth of cancer cell lines. Momordicoside G stimulates M2-associated lung injury repair and prevents inflammatory lung cancer injury .
    Momordicoside G
  • HY-103617
    PKM2-IN-1
    10+ Cited Publications

    Pyruvate Kinase Cancer
    PKM2-IN-1 (compound 3k) is a pyruvate kinase M2 (PKM2) inhibitor with an IC50 of 2.95 μM .
    PKM<em>2</em>-IN-1
  • HY-14825

    SVT-40776

    mAChR Neurological Disease
    Tarafenacin(SVT-40776) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.
    Tarafenacin
  • HY-70053A

    mAChR Neurological Disease Metabolic Disease
    Fesoterodine L-mandelate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine L-mandelate is used for the overactive bladder (OAB) [2].
    Fesoterodine L-mandelate
  • HY-I0230
    Solifenacin hydrochloride
    2 Publications Verification

    YM905 hydrochloride

    mAChR Neurological Disease Cancer
    Solifenacin hydrochloride (YM905 hydrochloride) is a muscarinic receptor antagonist, with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
    Solifenacin hydrochloride
  • HY-U00104

    mAChR Endocrinology
    YM-46303 is an mAChR antagonist which exhibits the highest affinities for M1 and M3 receptors, and selectivity for M3 over M2 receptor.
    YM-46303
  • HY-N7421

    Others Neurological Disease
    Smilagenin acetate is a sapogenin derivative extracted from patent US20030004147A1. Smilagenin acetate increases the expression of acetylcholine m2 receptors and can be used for the research of dementia .
    Smilagenin acetate
  • HY-117008

    PGE synthase Inflammation/Immunology
    CAY10589 is an inhibitor of mPGES-1, an enzyme induced during inflammatory responses. CAY10589 has no significant effect on the differentiation of BM myeloid precursor cells into M2-like TAMs [2].
    CAY10589
  • HY-A0002
    Solifenacin Succinate
    2 Publications Verification

    YM905

    mAChR Neurological Disease
    Solifenacin Succinate (YM905) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
    Solifenacin Succinate
  • HY-101381
    Otenzepad
    1 Publications Verification

    AF-DX 116

    mAChR Neurological Disease Metabolic Disease
    Otenzepad (AF-DX 116) is a selective and competitive M2 muscarinic acetylcholine receptor antagonist, with IC50 values of 640 nM and 386 nM for rabbit peripheral lung and rat heart, respectively .
    Otenzepad
  • HY-14825A

    SVT-40776 D-tartrate

    mAChR Neurological Disease
    Tarafenacin D-tartrate (SVT-40776 D-tartrate) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.
    Tarafenacin D-tartrate
  • HY-A0034
    Solifenacin
    2 Publications Verification

    YM905 free base

    mAChR Neurological Disease
    Solifenacin (YM905 free base) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
    Solifenacin
  • HY-119953

    mAChR Neurological Disease
    BIBN-99 is a selective, BBB-penetrable and competitive muscarinic M2 receptor antagonist. BIBN-99 improves cognitive performancein rats with traumatic brain injury [2].
    BIBN-99
  • HY-128525

    Others Infection Inflammation/Immunology
    Enterobactin is a bacterial siderophore that promotes iron absorption and can be used to study inflammation. Enterobactin also disrupts macrophage (MΦs) iron homeostasis and M1/M2 polarization to protect intracellular bacteria from host antimicrobial effects .
    Enterobactin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: